FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019969212> ?p ?o ?g. }

• W2019969212 endingPage "231.e9" @default.
• W2019969212 startingPage "231.e1" @default.
• W2019969212 abstract "Objective The purpose of this study was to compare primary debulking surgery (PDS) vs neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) among obese patients. Study Design Medical records of patients with a body mass index (BMI) of ≥30 kg/m2 with ovarian/fallopian tube/primary peritoneal carcinoma between January 2005 and December 2010 were reviewed. Patients were separated by PDS or NACT-IDS. Preoperative characteristics, surgical procedures, and postoperative and oncologic outcomes were compared. Results Of 117 patients, 95 women (81.2%) underwent PDS, and 22 women (18.8%) underwent NACT-IDS. Patients who underwent NACT-IDS were more likely to have stage IV disease (63.6% vs 26.3%; P = .001) and a low surgical complexity score (n = 14; 63.6%). There were no other differences between groups with respect to preoperative characteristics or postoperative morbidity. Compared with the NACT-IDS group, the PDS group had an improved progression-free survival (PFS; 15 vs 11 months; P = .006) and overall survival (OS; 53 vs 32 months; P = .036). Seventy-eight patients (66.7%) had a BMI of 30-34.9 kg/m2. Within this subset of obese patients, the PDS group had an improved PFS (15 vs 10 months; P = .011) and OS (58 vs 32 months; P = .033), compared with the NACT-IDS group. Among patients with a BMI of ≥35 kg/m2, there was no difference in PFS (14 vs 12 months; P = .316) or OS (38 vs 32 months; P = .640) when the PDS and NACT-IDS groups were compared. Conclusion Patients with a BMI of 30-34.9 kg/m2 who undergo PDS have improved oncologic outcomes, compared with those women who undergo NACT-IDS. Patients with a BMI of ≥35 kg/m2 who undergo PDS have similar oncologic outcomes to those who undergo NACT-IDS. Complication rates were similar at all BMIs, regardless of treatment approach. The purpose of this study was to compare primary debulking surgery (PDS) vs neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) among obese patients. Medical records of patients with a body mass index (BMI) of ≥30 kg/m2 with ovarian/fallopian tube/primary peritoneal carcinoma between January 2005 and December 2010 were reviewed. Patients were separated by PDS or NACT-IDS. Preoperative characteristics, surgical procedures, and postoperative and oncologic outcomes were compared. Of 117 patients, 95 women (81.2%) underwent PDS, and 22 women (18.8%) underwent NACT-IDS. Patients who underwent NACT-IDS were more likely to have stage IV disease (63.6% vs 26.3%; P = .001) and a low surgical complexity score (n = 14; 63.6%). There were no other differences between groups with respect to preoperative characteristics or postoperative morbidity. Compared with the NACT-IDS group, the PDS group had an improved progression-free survival (PFS; 15 vs 11 months; P = .006) and overall survival (OS; 53 vs 32 months; P = .036). Seventy-eight patients (66.7%) had a BMI of 30-34.9 kg/m2. Within this subset of obese patients, the PDS group had an improved PFS (15 vs 10 months; P = .011) and OS (58 vs 32 months; P = .033), compared with the NACT-IDS group. Among patients with a BMI of ≥35 kg/m2, there was no difference in PFS (14 vs 12 months; P = .316) or OS (38 vs 32 months; P = .640) when the PDS and NACT-IDS groups were compared. Patients with a BMI of 30-34.9 kg/m2 who undergo PDS have improved oncologic outcomes, compared with those women who undergo NACT-IDS. Patients with a BMI of ≥35 kg/m2 who undergo PDS have similar oncologic outcomes to those who undergo NACT-IDS. Complication rates were similar at all BMIs, regardless of treatment approach." @default.
• W2019969212 created "2016-06-24" @default.
• W2019969212 creator A5008611385 @default.
• W2019969212 creator A5014639724 @default.
• W2019969212 creator A5019240868 @default.
• W2019969212 creator A5025921511 @default.
• W2019969212 creator A5076333758 @default.
• W2019969212 creator A5080835546 @default.
• W2019969212 creator A5083352688 @default.
• W2019969212 creator A5085256262 @default.
• W2019969212 creator A5086662756 @default.
• W2019969212 creator A5089158382 @default.
• W2019969212 date "2014-09-01" @default.
• W2019969212 modified "2023-10-18" @default.
• W2019969212 title "What is the optimal treatment for obese patients with advanced ovarian carcinoma?" @default.
• W2019969212 cites W1569929411 @default.
• W2019969212 cites W1770712556 @default.
• W2019969212 cites W1804059878 @default.
• W2019969212 cites W1941585236 @default.
• W2019969212 cites W1965429276 @default.
• W2019969212 cites W1967518527 @default.
• W2019969212 cites W1974289641 @default.
• W2019969212 cites W1976568734 @default.
• W2019969212 cites W1986147394 @default.
• W2019969212 cites W2033051283 @default.
• W2019969212 cites W2038460625 @default.
• W2019969212 cites W2038736601 @default.
• W2019969212 cites W2046859247 @default.
• W2019969212 cites W2048602876 @default.
• W2019969212 cites W2049381419 @default.
• W2019969212 cites W2054531954 @default.
• W2019969212 cites W2055469801 @default.
• W2019969212 cites W2055543087 @default.
• W2019969212 cites W2056769925 @default.
• W2019969212 cites W2061729278 @default.
• W2019969212 cites W2073985767 @default.
• W2019969212 cites W2074033060 @default.
• W2019969212 cites W2077402071 @default.
• W2019969212 cites W2077488688 @default.
• W2019969212 cites W2077796933 @default.
• W2019969212 cites W2079076730 @default.
• W2019969212 cites W2106651817 @default.
• W2019969212 cites W2106767659 @default.
• W2019969212 cites W2112736878 @default.
• W2019969212 cites W2116996913 @default.
• W2019969212 cites W2130941707 @default.
• W2019969212 cites W2142929214 @default.
• W2019969212 cites W2148374907 @default.
• W2019969212 cites W2152807596 @default.
• W2019969212 cites W2154885792 @default.
• W2019969212 cites W2160707218 @default.
• W2019969212 cites W2166630111 @default.
• W2019969212 cites W2916596946 @default.
• W2019969212 doi "https://doi.org/10.1016/j.ajog.2014.03.059" @default.
• W2019969212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24704062" @default.
• W2019969212 hasPublicationYear "2014" @default.
• W2019969212 type Work @default.
• W2019969212 sameAs 2019969212 @default.
• W2019969212 citedByCount "8" @default.
• W2019969212 countsByYear W20199692122014 @default.
• W2019969212 countsByYear W20199692122015 @default.
• W2019969212 countsByYear W20199692122016 @default.
• W2019969212 countsByYear W20199692122017 @default.
• W2019969212 countsByYear W20199692122018 @default.
• W2019969212 countsByYear W20199692122019 @default.
• W2019969212 crossrefType "journal-article" @default.
• W2019969212 hasAuthorship W2019969212A5008611385 @default.
• W2019969212 hasAuthorship W2019969212A5014639724 @default.
• W2019969212 hasAuthorship W2019969212A5019240868 @default.
• W2019969212 hasAuthorship W2019969212A5025921511 @default.
• W2019969212 hasAuthorship W2019969212A5076333758 @default.
• W2019969212 hasAuthorship W2019969212A5080835546 @default.
• W2019969212 hasAuthorship W2019969212A5083352688 @default.
• W2019969212 hasAuthorship W2019969212A5085256262 @default.
• W2019969212 hasAuthorship W2019969212A5086662756 @default.
• W2019969212 hasAuthorship W2019969212A5089158382 @default.
• W2019969212 hasConcept C121608353 @default.
• W2019969212 hasConcept C126322002 @default.
• W2019969212 hasConcept C141071460 @default.
• W2019969212 hasConcept C146357865 @default.
• W2019969212 hasConcept C151730666 @default.
• W2019969212 hasConcept C195910791 @default.
• W2019969212 hasConcept C2776694085 @default.
• W2019969212 hasConcept C2777546739 @default.
• W2019969212 hasConcept C2780221984 @default.
• W2019969212 hasConcept C2780427987 @default.
• W2019969212 hasConcept C2781100745 @default.
• W2019969212 hasConcept C3019054536 @default.
• W2019969212 hasConcept C71924100 @default.
• W2019969212 hasConcept C86803240 @default.
• W2019969212 hasConceptScore W2019969212C121608353 @default.
• W2019969212 hasConceptScore W2019969212C126322002 @default.
• W2019969212 hasConceptScore W2019969212C141071460 @default.
• W2019969212 hasConceptScore W2019969212C146357865 @default.
• W2019969212 hasConceptScore W2019969212C151730666 @default.
• W2019969212 hasConceptScore W2019969212C195910791 @default.
• W2019969212 hasConceptScore W2019969212C2776694085 @default.
• W2019969212 hasConceptScore W2019969212C2777546739 @default.

• next